rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sarah Gheuens

Chief Medical Officer

Company insider

Files Form 4 as: Chief Medical Officer, Agios Pharmaceuticals; Director, Viridian Therapeutics.

In numbers

Trades disclosed
138
Buys
0
Sells
20
Bought
$0
Sold
$4.3M
Companies
2
Companies where not an officer
1
First trade
2 Dec 2021
Last trade
22 Oct 2026
Last filed
23 Oct 2026

Companies traded

Where they are an officer
AGIO Agios PharmaceuticalsOfficer · Biotechnology · last 22 Oct 20260 buys · 20 sells
Everywhere else they filed: board seats, 10% stakes, other companies
VRDN Viridian TherapeuticsDirector · Biotechnology · last 1 Jul 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
22 Oct 2026filed 23 Oct 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Code M$13K500 at $25.01filing
22 Oct 2026filed 23 Oct 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$19K500 at $37.52filing
22 Oct 2026filed 23 Oct 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—500 at $0.00filing
21 Oct 2026filed 23 Oct 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Code M$37K1,489 at $25.01filing
21 Oct 2026filed 23 Oct 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$56K1,489 at $37.53filing
21 Oct 2026filed 23 Oct 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—1,489 at $0.00filing
4 Aug 2026filed 6 Aug 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$914K30,000 at $30.48filing
4 Aug 2026filed 6 Aug 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$914K30,000 at $30.48filing
1 Jul 2026filed 2 Jul 2026VRDN Viridian Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,341 at $0.00filing
1 Jul 2026filed 2 Jul 2026VRDN Viridian Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,341 at $0.00filing
1 Jul 2026filed 2 Jul 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Code M—8,375 at $0.00filing
1 Jul 2026filed 2 Jul 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$151K4,007 at $37.56filing
1 Jul 2026filed 2 Jul 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—8,375 at $0.00filing
1 Jul 2026filed 2 Jul 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—8,375 at $0.00filing
1 Jul 2026filed 2 Jul 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Code M—8,375 at $0.00filing
1 Jul 2026filed 2 Jul 2026AGIO Agios PharmaceuticalsBiotechnologySEC FORM 4 Sold$151K4,007 at $37.56filing
18 Jun 2026filed 23 Jun 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—3,000 at $0.00filing
18 Jun 2026filed 23 Jun 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,000 at $0.00filing
18 Jun 2026filed 23 Jun 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—3,000 at $0.00filing
18 Jun 2026filed 23 Jun 2026AGIO Agios Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—3,000 at $0.00filing

Sectors

Health Care20

Buys in green, sells in red, by the company’s sector.

Related people

Jay T. BackstromDirector · Director at Agios Pharmaceuticals, filing Form 4 there in the last year
Kaye I. Foster-CheekDirector · Director at Agios Pharmaceuticals, filing Form 4 there in the last year
Jacqualyn A. FouseDirector · Director at Agios Pharmaceuticals, filing Form 4 there in the last year
Brian GoffChief Executive Officer · Chief Executive Officer at Agios Pharmaceuticals, filing Form 4 there in the last year
Cynthia SmithDirector · Director at Agios Pharmaceuticals, filing Form 4 there in the last year
Gilbert Ray Cisneros, Jr.Representative, CA-31 · Also traded AGIO in the last 90 days